Male C57BL/6J mice received either Ara-C (275 mg/kg i.p. daily for 5 days) or saline.
Methodology/Principal Findings: Liver fibrosis was induced in mice by repeated carbon tetrachloride (CCl4) administration, during which the mice received either Marimastat or vehicle twice daily.
However, mice received either anti-IL-6R MC-DNA or CsA presented prolonged acceptance of graft until day 15 or 15.6, respectively.
Four- to six-week old female mice received either subcutaneous (s.c).
Control mice received either 6 MBq (25 μg) of a 177Lu-labelled unspecific control IgG or PBS.
Male mice received either saline or 15-81 kBq/g and females received either saline or 16-83 kBq/g of 211At-labeled antibody.
The HNP+/+and the FVB wild type mice received either HCl (pH = 1.0, 3 mL/kg) intratracheally, or vehicle solution as a control.
To assess the potential toxic effects of the MSC-NTF cells, the mice received either single or repeated IM injections to the quadriceps femoris muscles.
For delivery studies, mice received either PBS, 1 × 107 AuNP-T cells, or 1 × 1011 PEGylated AuNPs via the tail vein in a 200 μL bolus.
These mice received either an intraperitoneal saline injection or a single dose of 15 mg/kg carboxymaltose ferric at week 1 (ID+I and CT+I groups).
Twenty-four hours later, mice received either 600 μg PTX (31.6 mg/kg, clinical formulation; Taxol, Bristol-Myers Switzerlandich, Switzerland, 1 3 dilution with PBS; 300 μl) i.p. or 300 μl PBS i.p.
